A new parcel of federal funding will help AIBN researchers produce clinical-grade mRNA products that are safer and better quality, and will potentially cost less.
Two exciting AIBN projects have scored new funding to help industry collaborators crack the lucrative computer chip industry and capitalise on opportunities in waste-to-catalyst conversion
Four AIBN-led projects have been recognised in latest round of the $220 million Australian Research Council Discovery scheme, a program that recognises research with economic, commercial, environmental, social and/or cultural benefits.
AIBN researchers are using the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.
Two rising research stars have shown just why the AIBN is renowned as an incubator for scientific talent, each securing $440,000 funding to accelerate their game-changing work.
AIBN group leader Dr Bin Luo and industry partner Redflow are cracking the code to better battery tech, pitting battery materials against each other to identify superior performance, improve costs, and identify degradation factors.
mRNA vaccines and therapies will be produced for clinical trials in a dedicated laboratory to be built at the Australian Institute for Bioengineering and Nanotechnology.
